Annual Reports in Medicinal Chemistry

Content: 
Copyright
Page iv

Contributors
Pages xv-xvi

Preface
Pages xvii-xviii
Manoj C. Desai

Chapter One - Reflections on Medicinal Chemistry at Merck, West Point
Pages 3-11
Paul S. Anderson

Chapter Two - My Path in Seeking New Medicines
Pages 13-24
Peter R. Bernstein

Chapter Three - Tales of Drug Discovery
Pages 25-34
M. Ross Johnson

Chapter Four - Recent Developments in Targeting Neuroinflammation in Disease
Pages 37-53
Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski, Roland G.W. Staal

Chapter Five - Secretase Inhibitors and Modulators as a Disease-Modifying Approach Against Alzheimer's Disease
Pages 55-69
Harrie J.M. Gijsen, François P. Bischoff

Chapter Six - mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders
Pages 71-88
Sylvain Célanire, Guillaume Duvey, Sonia Poli, Jean-Philippe Rocher

Chapter Seven - NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments
Pages 89-103
Kamalesh B. Ruppa, Dalton King, Richard E. Olson

Chapter Eight - Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging
Pages 105-119
Lei Zhang, Anabella Villalobos

Chapter Nine - Case History: Eliquis™ (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases
Pages 123-141
Donald J.P. Pinto, Pancras C. Wong, Robert M. Knabb, Ruth R. Wexler

Chapter Ten - AMPK Activation in Health and Disease
Pages 143-157
Iyassu K. Sebhat, Robert W. Myers

Chapter Eleven - Type-2 Diabetes and Associated Comorbidities as an Inflammatory Syndrome
Pages 159-175
Juan C. Jaen, Jay P. Powers, Tim Sullivan

Chapter Twelve - Beyond PPARs and Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes
Pages 177-192
Philip A. Carpino, David Hepworth

Chapter Thirteen - Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists
Pages 195-207
Alaric J. Dyckman

Chapter Fourteen - Bifunctional Compounds for the Treatment of COPD
Pages 209-221
Gary Phillips, Michael Salmon

Chapter Fifteen - Inflammatory Targets for the Treatment of Atherosclerosis
Pages 223-235
Robert O. Hughes, Alessandra Bartolozzi, Hidenori Takahashi

Chapter Sixteen - Nanotechnology Therapeutics in Oncology—Recent Developments and Future Outlook
Pages 239-252
Paul F. Richardson

Chapter Seventeen - Small-Molecule Antagonists of Bcl-2 Family Proteins
Pages 253-266
Sean P. Brown, Joshua P. Taygerly

Chapter Eighteen - Notch Pathway Modulators as Anticancer Chemotherapeutics
Pages 267-280
Vibhavari Sail, M. Kyle Hadden

Chapter Nineteen - Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers
Pages 281-293
Kazutomo Kinoshita, Nobuhiro Oikawa, Takuo Tsukuda

Chapter Twenty - Recent Advances in the Discovery of Dengue Virus Inhibitors
Pages 297-317
Jeremy Green, Upul Bandarage, Kate Luisi, Rene Rijnbrand

Chapter Twenty-One - Nonfluoroquinolone-Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB
Pages 319-330
Pravin S. Shirude, Shahul. Hameed

Chapter Twenty-Two - HCV Inhibition Mediated Through the Nonstructural Protein 5A (NS5A) Replication Complex
Pages 331-345
Robert Hamatake, Andrew Maynard, Wieslaw M. Kazmierski

Chapter Twenty-Three - Antibody–Drug Conjugates for Targeted Cancer Therapy
Pages 349-366
Victor S. Goldmacher, Thomas Chittenden, Ravi V.J. Chari, Yelena V. Kovtun, John M. Lambert

Chapter Twenty-Four - 3D Cell Cultures: Mimicking In Vivo Tissues for Improved Predictability in Drug Discovery
Pages 367-378
Indira Padmalayam, Mark J. Suto

Chapter Twenty-Five - Virally Encoded G Protein-Coupled Receptors: Overlooked Therapeutic Opportunities?
Pages 379-392
Nuska Tschammer

Chapter Twenty-Six - Recent Advances in Wnt/β-Catenin Pathway Small-Molecule Inhibitors
Pages 393-409
Daniel D. Holsworth, Stefan Krauss

Chapter Twenty-Seven - Targeted Covalent Enzyme Inhibitors
Pages 413-439
Mark C. Noe, Adam M. Gilbert

Chapter Twenty-Eight - Drug Design Strategies for GPCR Allosteric Modulators
Pages 441-457
P. Jeffrey Conn, Scott D. Kuduk, Darío Doller

Chapter Twenty-Nine - Progress in the Development of Non-ATP-Competitive Protein Kinase Inhibitors for Oncology
Pages 459-474
Campbell McInnes

Chapter Thirty - New Chemical Entities Entering Phase III Trials in 2011
Pages 477-498
Gregory T. Notte

Chapter Thirty-One - To Market, To Market—2011
Pages 499-569
Joanne Bronson, Murali Dhar, William Ewing, Nils Lonberg

Keyword Index, Volume 47
Pages 571-580

Cumulative Chapter Titles Keyword Index, Volume 1 – 47
Pages 581-603

Cumulative NCE Introduction Index, 1983-2011
Pages 605-628

Cumulative NCE Introduction Index, 1983-2011 (by indication)
Pages 629-652